Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz has maintained a Neutral rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and lowered the price target from $94 to $91.

April 25, 2024 | 10:48 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup maintains a Neutral rating on Biomarin Pharmaceutical and lowers the price target from $94 to $91.
The adjustment in price target by Citigroup reflects a slight negative sentiment towards Biomarin Pharmaceutical's short-term stock price potential, but the maintenance of a Neutral rating suggests no significant change in the company's overall outlook. The reduction in price target might lead to short-term investor caution, but the unchanged rating indicates stability in the analyst's view of the company's fundamentals.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100